Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 17Myelodysplastic Syndromes 9Leukemia, Myelomonocytic, Chronic 4Myeloproliferative Disorders 3Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Biphenotypic, Acute 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Primary Myelofibrosis 1Polycythemia Vera 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Hodgkin Disease 1GATA2 Deficiency 1Cytopenia 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1BRCA1 Mutation 1Anemia, Refractory, with Excess of Blasts 1Allogeneic Stem Cell Transplantation 1

Interventions

pembrolizumab 7avelumab 6Nivolumab 6Specimen Handling 5Magnetic Resonance Spectroscopy 4Biopsy 4Ipilimumab 3prednylidene 2lutetium Lu 177 dotatate 2deltacortene 2Radiosurgery 2Prednisone 2Immunoglobulin G 2Cyclophosphamide 2CTLA-4 Antigen 2talimogene laherparepvec 1sargramostim 1lenvatinib 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1cemiplimab 1atezolizumab 1aldesleukin 1X-Rays 1Tacrolimus 1Sirolimus 1Saline Solution 1Radiotherapy 1MAPRE1 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Merkel Cell × decitabine and cedazuridine drug combination × 90 days × Clear all
NCT07472322 2026-05-29

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

University of Wisconsin, Madison

Phase 1/2 Not yet recruiting
31 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡